Browse the evidence

No clinically relevant differences in generic health-related quality of life (HRQoL) were observed between sleeve gastrectomy and Roux-en-Y gastric bypass.

Clinicians can expect similar HRQoL outcomes from both surgical options for patients with severe obesity.

Cardiovascular autonomic neuropathy (CAN) is not significantly associated with mortality in men with type 2 diabetes.

Men with type 2 diabetes may require different monitoring strategies for mortality risk compared to women.

There was no association found between weight loss and improvement in FEV1 or FVC.

Weight loss from GLP-1 therapies may not lead to improvements in lung function, indicating the need for further investigation.

Side effects were common and led to discontinuation of the medication in 18.5% of patients.

Clinicians should monitor for side effects in patients on GLP-1 therapies, as they may affect treatment adherence.

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

Semaglutide is projected to increase annual health care spending by $23 billion.

Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

No significant associations were found between GLP-1 receptor agonists or SGLT2 inhibitors and risk of sepsis, abscess, gangrene, or other infections.

Practitioners can be reassured about the lack of infection risk associated with these medications.

Obesity is projected to affect over half of the global population by 2035.

Healthcare providers should prepare for increased obesity-related challenges.

Advances in omics technologies have enabled the identification of molecular subtypes and candidate biomarkers for obesity.

Utilizing omics technologies can enhance personalized approaches to obesity treatment.

The net financial impact to Medicare was estimated to be savings of $715 million over 10 years.

Healthcare policymakers should recognize the potential cost savings associated with semaglutide for Medicare.

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

Further research is needed to assess the long-term safety of Tirzepatide, particularly regarding cardiovascular outcomes.

Practitioners should be aware of the need for ongoing evaluation of Tirzepatide's long-term safety profile.

Interdisciplinary collaboration and communication between anaesthetists, surgeons, general practitioners, and endocrinologists are required to further investigate and establish preoperative guidelines for safe GLP-1 agonist use.

Healthcare teams should work together to create and follow guidelines for managing patients on GLP-1 agonists in surgical settings.

62% of protein supplement users were male.

Practitioners should note the gender distribution in protein supplement use.

42% of protein supplement users were aged 25–34.

Targeted educational initiatives can be focused on this age group.

Management of GLP-1RA adverse events lacks evidence-based support.

Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.

Rifampicin inhibits body weight gain in high-fat diet-fed mice.

Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.

Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.

NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.

Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.

Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.

Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).

Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.

There were no reports of pharmacotherapies for weight management in the studies reviewed.

Practitioners should be aware that pharmacotherapy options are not currently reported for this population.

Hepatotoxicity is not a widely recognized complication of tirzepatide.

Awareness of potential liver injury should be increased among healthcare providers prescribing tirzepatide.

The previous version of the guideline did not include a literature review for obesity surgery due to limited resources, and it references an existing guideline for obesity surgery.

Clinicians should be aware of the referenced guidelines for obesity surgery when making treatment decisions.